Disorders Due to Use of Synthetic Cathinones (ICD-11: 6C47)

1. Introduction

Disorders due to the use of synthetic cathinones represent an emerging and significant challenge for global public health. These substances, often marketed under deceptive names such as "bath salts," "plant fertilizers," or "cleaning products," are synthetic psychoactive compounds that mimic the stimulant effects of natural cathinone, found in the khat plant (Catha edulis). Despite the seemingly harmless nomenclature used for their marketing, these substances possess significant potential to cause dependence, severe intoxication, and various mental disorders.

The clinical importance of disorders related to synthetic cathinones has grown substantially over the past decades, particularly among young populations seeking legal or easily accessible alternatives to traditional stimulants. The constantly evolving nature of these substances, with new analogs being synthesized regularly to circumvent legislation, makes the recognition and treatment of these disorders particularly challenging for healthcare professionals.

The impact on public health is considerable, with reports of serious medical emergencies, violent behaviors, drug-induced psychosis, and even fatalities associated with the use of these substances. Correct coding through the ICD-11 code 6C47 is fundamental for adequate epidemiological monitoring, health resource planning, development of effective public policies, and assurance of appropriate treatment for affected patients. Furthermore, precise documentation facilitates scientific research and enables international comparisons regarding the prevalence and impact of these disorders.

2. Correct ICD-11 Code

Code: 6C47

Description: Disorders due to use of synthetic cathinones

Parent category: Disorders due to substance use

Official definition: Disorders due to use of synthetic cathinones are characterized by the pattern and consequences of synthetic cathinone use. Synthetic cathinones, also popularly known as "bath salts," are synthetic compounds with stimulant properties related to cathinone found in the khat plant, Catha edulis. The use of synthetic cathinones is common in young populations in many countries and can produce a range of disorders, including synthetic cathinone intoxication, synthetic cathinone dependence, and synthetic cathinone withdrawal.

This code encompasses various mental disorders induced by synthetic cathinones, recognizing that these substances can cause not only dependence but also significant psychiatric manifestations such as psychosis, anxiety, depression, and other mood disorders. The ICD-11 classification recognizes the complexity of use patterns and the multiple clinical consequences associated with these substances, allowing for a more comprehensive and specific diagnostic approach than was possible in previous classification systems.

The specific inclusion of synthetic cathinones as its own category reflects growing awareness of the unique risks of these substances and the need to differentiate them from other synthetic or natural stimulants for purposes of treatment and epidemiological surveillance.

3. When to Use This Code

Code 6C47 should be used in specific clinical situations where there is clear evidence of disorders related to the use of synthetic cathinones. Below are detailed practical scenarios:

Scenario 1: Established dependence with functional impairment A 24-year-old patient presents with a history of regular use of mephedrone (4-MMC) over the past 18 months, with progressively increased consumption. Reports inability to control use, failed attempts to stop, abandonment of professional and social activities, and continues using despite recognizing mental health problems (intense anxiety and paranoia). There are clear criteria for dependence with significant impairment of daily functioning.

Scenario 2: Acute intoxication with severe manifestations A patient arrives at the emergency department in a state of extreme psychomotor agitation, tachycardia, hypertension, hyperthermia, and aggressive behavior following confirmed use of alpha-PVP ("flakka"). Presents with visual hallucinations and paranoid delusions. Family members confirm recent use of a substance acquired as "bath salts." This presentation of acute intoxication by synthetic cathinone justifies the use of code 6C47.

Scenario 3: Documented withdrawal syndrome An hospitalized patient reports daily use of methylone for six months, having abruptly stopped 48 hours ago. Presents with intense fatigue, depressed mood, marked anhedonia, hypersomnia, increased appetite, and intense craving for the substance. These withdrawal symptoms specific to synthetic cathinones require coding 6C47.

Scenario 4: Psychotic disorder induced by synthetic cathinones A patient with no previous psychiatric history develops acute psychotic presentation with persecutory delusions, auditory hallucinations, and disorganized thinking following repeated use of MDPV during a music festival. Symptoms persist beyond the period of acute intoxication, characterizing psychotic disorder induced by synthetic cathinone.

Scenario 5: Pattern of harmful use without complete dependence A young patient uses mephedrone episodically in recreational contexts, resulting in risky behaviors (driving while intoxicated, unprotected sexual relations), recurrent interpersonal problems, and episodes of intense post-use anxiety. Although not meeting full criteria for dependence, there is a pattern of harmful use clearly related to synthetic cathinones.

Scenario 6: Anxiety disorder induced by synthetic cathinones A patient develops recurrent panic attacks and generalized anxiety following a period of regular use of pentylone, with symptoms persisting even after cessation of use. The temporal and causal relationship between substance use and the development of anxiety disorder justifies code 6C47 with specification of the induced mental disorder.

4. When NOT to Use This Code

It is fundamental to recognize situations where code 6C47 is not appropriate, avoiding diagnostic confusion and ensuring accurate coding:

Use of traditional stimulants: When the disorder is related to the use of cocaine, prescribed amphetamines, or methamphetamine, specific codes for these substances should be used (6C44 for cocaine, 6C46 for amphetamines). Even if the pattern of use is similar, the specific substance determines the correct code.

Primary psychiatric disorders: If the patient has a well-established history of bipolar disorder, schizophrenia, or another primary psychiatric disorder that precedes the use of synthetic cathinones, and the use of the substance is not the primary causal factor of current symptoms, the code for the primary disorder should be prioritized. Substance use may be coded additionally, but not as the principal diagnosis.

Isolated recreational use without consequences: Report of single experimental or occasional use of synthetic cathinones without development of a problematic pattern, dependence, significant intoxication, or other related disorders does not justify the use of code 6C47. There must be evidence of clinically significant disorder.

Intoxication by other novel psychoactive substances: With the proliferation of synthetic substances, it is crucial to correctly identify the chemical class. Synthetic cannabinoids (6C42), synthetic opioids, or other classes of novel psychoactive substances have specific codes and should not be classified as synthetic cathinones.

Adverse reactions to prescribed medications: If similar symptoms occur as an adverse reaction to legitimately prescribed stimulant medications (such as methylphenidate for ADHD), codes for adverse drug reactions are more appropriate, not codes for substance use disorders.

5. Step-by-Step Coding Process

Step 1: Assess diagnostic criteria

Confirmation of diagnosis requires comprehensive clinical evaluation that includes:

Detailed substance use history: Specifically investigate the use of "bath salts," products sold as "not intended for human consumption," or substances known by street names such as "flakka," "drone," "M-CAT," or others. Document the specific substance when possible (mephedrone, MDPV, alpha-PVP, methylone, pentylone), frequency, quantity, route of administration, and duration of use.

Assessment of dependence criteria: Use validated instruments when available, but clinically evaluate: impaired control over use, increasing prioritization of the substance over other activities, continued use despite negative consequences, tolerance (need for larger doses), and withdrawal symptoms.

Mental status examination: Assess presence of current psychiatric symptoms, including mood alterations, anxiety, psychotic symptoms, cognitive impairment, and risk-taking behaviors. Determine whether these symptoms are consistent with intoxication, withdrawal, or substance-induced disorders.

Complementary tests: When available, toxicological tests can confirm recent use, although standard tests frequently do not detect synthetic cathinones, requiring specialized panels. Assessment of vital signs and medical complications (cardiovascular, renal, hepatic) is essential.

Step 2: Verify specifiers

After confirming the diagnosis, specify:

Type of disorder: Identify whether it is a single episode of intoxication, harmful use, dependence, withdrawal, or substance-induced mental disorder (psychotic, mood, anxiety, etc.). ICD-11 has specific subcategories within code 6C47 for these different disorders.

Severity: Assess severity based on the number of criteria present, degree of functional impairment, and presence of medical or psychiatric complications. Categorize as mild, moderate, or severe as appropriate.

Temporal course: Document whether the disorder is current (symptoms present), in early remission (without criteria for 1-12 months), or in sustained remission (more than 12 months without criteria). For induced disorders, specify whether they occur during intoxication, withdrawal, or persist beyond these periods.

Associated features: Document medical complications, context of use (recreational, self-medication), polysubstance use patterns, and relevant psychosocial factors.

Step 3: Differentiate from other codes

6C40 - Disorders due to use of alcohol: Although both alcohol and synthetic cathinones can cause dependence and intoxication, differentiate by the substance used. Cathinones produce stimulant effects (agitation, insomnia, paranoia), while alcohol is a depressant. History of use and toxicological examination are determinant.

6C41 - Disorders due to use of cannabis: Cannabis generally produces relaxation, perceptual alterations, and increased appetite, contrasting with the stimulant and frequently anxiety-inducing effects of cathinones. Clinical presentation and history of use clearly distinguish these conditions.

6C42 - Disorders due to use of synthetic cannabinoids: This is a crucial differentiation, as both are synthetic substances frequently sold in similar ways. Synthetic cannabinoids (K2, Spice) act on cannabinoid receptors, producing effects similar to intensified cannabis. Synthetic cathinones are stimulants that act on monoaminergic systems, with a clinical profile similar to amphetamines. Clinical presentation (stimulation vs. sedation/perceptual alterations) is fundamental for distinction.

6C44 - Disorders due to use of cocaine: Although synthetic cathinones and cocaine are both stimulants, the distinction is based on the specific substance used. Clinically, cathinones may produce more prolonged effects and more frequent psychotic symptoms than cocaine.

6C46 - Disorders due to use of amphetamines: This is the most challenging differentiation, as synthetic cathinones and amphetamines have similar pharmacological profiles. The distinction is based on specific identification of the substance used. Cathinones are beta-keto analogs of amphetamines, structurally related but chemically distinct.

Step 4: Required documentation

Checklist of mandatory information:

Specific substance identification (chemical name, street name, physical description of product)
Detailed use pattern: frequency, quantity, route of administration, total duration of use
Specific diagnostic criteria present (for dependence, list which criteria are present)
Symptoms of intoxication or withdrawal documented objectively
Medical, psychiatric, social, occupational, and legal consequences of use
Previous cessation attempts and prior treatments
History of use of other substances (polysubstance use)
Psychiatric and medical comorbidities
Complementary tests performed (toxicology, laboratory, imaging)
Risk assessment (suicidality, violent behaviors, medical vulnerabilities)

Adequate documentation: Documentation should be sufficiently detailed to justify the chosen code, allow continuity of care, and serve epidemiological and research purposes. Use clear and objective terminology, avoiding jargon or ambiguities.

6. Complete Practical Example

Clinical Case

Initial presentation: A 22-year-old male patient, university student, is brought to the emergency department by friends after displaying bizarre and aggressive behavior at a party. He is in a state of intense psychomotor agitation, profuse diaphoresis, dilated pupils, tachycardia (140 bpm) and hypertension (170/110 mmHg). He presents with disorganized speech, reports being persecuted by "entities" and attempts to flee repeatedly. Body temperature of 39.2°C.

Evaluation performed: Friends report that the patient consumed a substance purchased online sold as "plant fertilizer" under the commercial name "Cloud 9," approximately 3 hours prior. They report that he has been using this substance with increasing frequency over the past 6 months, initially only at parties, but recently almost daily. They inform that he has presented with behavioral changes, social isolation, abandonment of academic activities and previous episodes of paranoia.

After initial stabilization, the patient remains hospitalized for 48 hours. As acute effects diminish, he confirms regular use of a substance he believes to be alpha-PVP (flakka), based on online descriptions. He reports that in recent months he has developed a need for progressively larger doses, spends significant financial resources on the substance, made multiple failed attempts to stop and acknowledges that use is ruining his academic life and relationships. When he attempts to stop, he experiences extreme fatigue, intense depression and uncontrollable craving.

Specialized toxicological testing confirms the presence of alpha-PVP. Psychiatric evaluation reveals psychotic symptoms (paranoid delusions and hallucinations) that persist beyond the period of acute intoxication, in addition to significant depressive and anxious symptoms.

Diagnostic reasoning: The case presents multiple components: (1) acute intoxication by synthetic cathinone with medical and psychiatric complications; (2) well-established pattern of dependence with multiple criteria present (impaired control, continued use despite consequences, tolerance, withdrawal, abandonment of activities); (3) psychotic disorder induced by synthetic cathinone that persists beyond acute intoxication.

Step-by-Step Coding

Criteria analysis:

Confirmed substance: alpha-PVP (synthetic cathinone)
Acute intoxication present: behavioral, psychotic and autonomic alterations
Established dependence: presence of at least 6 criteria (impaired control, failed cessation attempts, excessive time dedicated to substance, craving, tolerance, withdrawal, continued use despite consequences, abandonment of activities)
Induced psychotic disorder: psychotic symptoms persisting beyond acute intoxication
Significant functional impairment: academic abandonment, social isolation

Code selected: 6C47 - Disorders due to use of synthetic cathinones

Specifications:

6C47.2 - Dependence on synthetic cathinones (primary code)
6C47.0 - Intoxication by synthetic cathinones (additional code for acute episode)
6C47.7 - Psychotic disorder induced by synthetic cathinones (additional code)

Complete justification: Code 6C47 is appropriate because the substance used (alpha-PVP) is definitively a synthetic cathinone, confirmed by history, clinical presentation and toxicological testing. Dependence is the primary diagnosis given the established pattern of problematic use with multiple criteria present and significant functional impairment. Acute intoxication justifies an additional code to document the episode that prompted presentation. The induced psychotic disorder also requires separate coding as it persists beyond intoxication and requires specific treatment.

Complementary codes:

Code for tachycardia (medical manifestation of intoxication)
Code for hyperthermia (medical complication)
Possible Z code for social context (abandonment of studies)

7. Related Codes and Differentiation

Within the Same Category

6C40: Disorders due to use of alcohol

When to use: When the disorder is specifically related to consumption of alcoholic beverages
Main difference: Alcohol is a central nervous system depressant, producing sedation, incoordination, and disinhibition. Synthetic cathinones are stimulants, causing agitation, insomnia, paranoia, and hyperactivity. The clinical presentation is fundamentally opposite.

6C41: Disorders due to use of cannabis

When to use: For disorders related to use of natural marijuana (Cannabis sativa/indica)
Main difference: Cannabis produces relaxation, mild to moderate perceptual alterations, increased appetite, and generally anxiety reduction (although it may cause anxiety in some users). Synthetic cathinones cause intense stimulation, appetite suppression, insomnia, and frequently severe anxiety and paranoia. The pharmacological and clinical profiles are completely distinct.

6C42: Disorders due to use of synthetic cannabinoids

When to use vs. 6C47: Use 6C42 when the substance is a synthetic cannabinoid (K2, Spice, JWH-018, etc.), which acts on cannabinoid receptors. Use 6C47 for synthetic cathinones that act on monoaminergic systems.
Main difference: Although both are synthetic "novel psychoactive substances" frequently sold similarly, the mechanisms of action and clinical effects are distinct. Synthetic cannabinoids produce intensified cannabis-like effects (perceptual alterations, relaxation or sedation, possible anxiety). Synthetic cathinones produce amphetamine-like effects (stimulation, euphoria, insomnia, agitation). Differentiation requires identification of the specific substance and recognition of the clinical profile.

6C44: Disorders due to use of cocaine

When to use vs. 6C47: Use 6C44 when the substance is cocaine (natural alkaloid from the coca plant). Use 6C47 for synthetic cathinones.
Main difference: Although both are stimulants with some overlapping effects, cocaine has a shorter half-life and briefer effects. Synthetic cathinones frequently produce more prolonged effects and greater incidence of psychotic symptoms. The distinction is based primarily on identification of the substance used.

6C46: Disorders due to use of amphetamines and methamphetamine

When to use vs. 6C47: Use 6C46 for amphetamines (including methamphetamine, MDMA/"ecstasy," prescribed amphetamine). Use 6C47 specifically for synthetic cathinones.
Main difference: This is the most subtle distinction, as synthetic cathinones are structurally related to amphetamines (they are beta-keto analogs). The clinical profiles are very similar. Differentiation requires specific chemical identification of the substance. Clinically, cathinones may have a greater tendency to cause psychotic symptoms and violent behavior, but this is not a reliable distinction. Substance identification through detailed history or toxicology is essential.

Differential Diagnoses

Primary psychotic disorders (Schizophrenia, Schizoaffective disorder): Differentiate based on temporal relationship between substance use and symptoms. In cathinone-induced psychotic disorders, symptoms typically begin during or shortly after use, improve with abstinence (although may persist for weeks), and there is no history of psychotic symptoms prior to initiation of substance use.

Bipolar disorder in mania: Manic episodes may resemble cathinone intoxication (euphoria, agitation, insomnia, risky behavior). Differentiate through detailed history, toxicological examination, and temporal pattern. In cathinone intoxication, symptoms are clearly related to substance use.

Primary anxiety disorders: Panic attacks and generalized anxiety may occur with synthetic cathinones. Differentiate by temporal relationship with substance use and by complete clinical context.

Delirium from other causes: Severe cathinone intoxication may cause delirium, but other medical causes (infections, metabolic disturbances, other intoxications) should be excluded through appropriate clinical and laboratory evaluation.

8. Differences with ICD-10

In ICD-10, there was no specific code for disorders due to the use of synthetic cathinones. These substances were generally classified under:

F15 - Mental and behavioral disorders due to use of other stimulants, including caffeine: This was the most commonly used code for synthetic cathinones in ICD-10, grouping them with other unspecified stimulants.

Main changes in ICD-11:

ICD-11 represents a significant advance by creating a specific code (6C47) for synthetic cathinones, recognizing:

Increased specificity: The separation of synthetic cathinones into their own category allows for more precise epidemiological tracking of this emerging class of substances, facilitating research, public health surveillance, and development of specific interventions.

Recognition of unique profile: Although related to amphetamines, synthetic cathinones have pharmacological and clinical characteristics sufficiently distinct to justify separate classification. This includes greater variability among different compounds, tendency toward more severe psychotic symptoms, and different safety profile.

Improved organizational structure: ICD-11 uses a more flexible and detailed system, allowing specification of subtypes (intoxication, dependence, withdrawal, induced disorders) through code extensions, while ICD-10 had a more rigid structure.

Practical impact:

For health professionals, the change requires familiarization with the new code and criteria. For health information systems, it enables more precise data on the prevalence and impact of synthetic cathinones. For researchers, it facilitates comparative studies. For policymakers, it provides more specific information to direct resources and interventions.

The transition from ICD-10 to ICD-11 requires training of professionals and updating of registration systems, but offers substantial benefits in terms of diagnostic accuracy and utility of collected data.

9. Frequently Asked Questions

1. How is the diagnosis of disorders due to synthetic cathinone use made?

The diagnosis is primarily clinical, based on detailed substance use history, assessment of characteristic signs and symptoms, and mental status examination. The healthcare professional should specifically investigate use of "bath salts," substances sold as "not intended for human consumption," or products purchased online or in specialized establishments. Specialized toxicological tests can confirm the diagnosis, but standard screening tests frequently do not detect synthetic cathinones, requiring specific panels that are not always available. Clinical presentation (stimulant effects, psychotic symptoms, use pattern) combined with reliable history is usually sufficient for diagnosis. Structured assessment instruments can assist in determining dependence criteria and severity.

2. Is treatment available in public health systems?

Treatment availability varies by region and local resources, but public health systems in many countries offer services for substance use disorders that can serve patients with problems related to synthetic cathinones. Treatment generally includes detoxification (when necessary), psychotherapy (particularly cognitive-behavioral therapy and motivational interviewing), management of psychiatric comorbidities, and psychosocial support. There are no specific medications approved for synthetic cathinone dependence, but symptomatic treatment of complications and comorbidities is provided. Support groups and rehabilitation programs may also be accessible through public systems or community organizations.

3. How long does treatment last?

Treatment duration varies significantly depending on dependence severity, presence of comorbidities, social support, and individual response. Acute detoxification generally requires days to weeks. Outpatient treatment for dependence typically lasts months, with many programs recommending a minimum of 3-6 months of active follow-up. For severe cases with multiple relapses or complex comorbidities, treatment may extend over years. Relapse prevention programs and long-term follow-up are important even after cessation of use, as relapse risk remains elevated. Treatment should be individualized, with duration adjusted to each patient's specific needs and therapeutic response.

4. Can this code be used in medical certificates?

Yes, code 6C47 can be used in official medical documentation, including certificates, when clinically appropriate and necessary. However, professionals should consider confidentiality and stigma issues. In many situations, it may be sufficient to use more general codes or describe specific symptoms (such as "acute psychiatric disorder" or "acute medical condition") without specifying substance use, especially in certificates for employers or educational institutions. The decision should balance legitimate medical documentation needs with patient privacy protection and minimization of potential negative consequences. Frank discussion with the patient about what will be documented and where is recommended practice.

5. Can synthetic cathinones be detected in routine drug screening tests?

Generally not. Standard toxicological screening tests (immunoassays commonly used in occupational or basic clinical settings) frequently do not detect synthetic cathinones because they are structurally different from substances included in standard panels. Detection requires more sophisticated methods such as gas chromatography-mass spectrometry (GC-MS) or liquid chromatography-mass spectrometry (LC-MS) with specific panels for novel psychoactive substances. These specialized tests are not always readily available and may be more expensive. Additionally, the constant emergence of new synthetic cathinone analogs makes it challenging to keep tests updated. Therefore, diagnosis often relies on clinical history and symptomatic presentation.

6. What are the most serious medical risks associated with synthetic cathinone use?

Synthetic cathinones present significant medical risks, including cardiovascular complications (tachycardia, hypertension, arrhythmias, myocardial infarction), potentially fatal hyperthermia (especially in warm environments or with intense physical activity), rhabdomyolysis (muscle breakdown that can cause renal failure), acute kidney injury, seizures, stroke, and serious psychiatric complications (psychosis, violent behavior, suicide). Deaths have been reported, often related to hyperthermia, cardiovascular complications, or risky behaviors during intoxication. Risk is increased by variability in composition and potency of illegally sold products, possibility of contaminants, and risky behaviors during intoxication.

7. Is there a difference in treatment compared to other stimulants?

General treatment principles are similar to those used for dependence on other stimulants (cocaine, amphetamines), as there are no specific approved pharmacological treatments for synthetic cathinones. The focus is on psychosocial interventions, particularly cognitive-behavioral therapy, contingency management, motivational interviewing, and relapse prevention. However, some aspects may require special attention: psychotic symptoms may be more prominent and prolonged, requiring more frequent antipsychotic treatment; specific education about synthetic cathinone risks is important; and addressing use contexts (often recreational in young populations) may require adapted strategies. Treatment of medical and psychiatric comorbidities follows standard principles.

8. How to approach patients who minimize or deny problems with use?

Denial and minimization are common in substance use disorders. Recommended approach includes: establishing a non-judgmental and empathetic therapeutic relationship; using motivational interviewing techniques to explore ambivalence and increase motivation for change; providing objective information about risks without confrontation; focusing on discrepancies between patient's values/goals and current behavior; involving family or significant others when appropriate and with consent; offering assessment and treatment of comorbidities that may be motivating use (anxiety, depression, insomnia); and keeping the door open for return even if patient is not ready for treatment immediately. Brief interventions can be effective even when patient does not fully recognize problem severity.

Conclusion:

The ICD-11 code 6C47 for disorders due to synthetic cathinone use represents important recognition of an emerging and clinically significant category of substance use disorders. Accurate coding requires understanding of the pharmacological and clinical characteristics of these substances, ability to differentiate them from other stimulants and synthetic substances, and comprehensive assessment of use patterns and consequences. With appropriate use of this code, healthcare professionals contribute to more precise epidemiological surveillance, adequate resource planning, and fundamentally, more effective clinical care for individuals affected by these disorders.

External References

This article was prepared based on reliable scientific sources:

References verified on 2026-02-03

Disorders Due to the Use of Synthetic Cathinones

Partager